Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in chronic heart failure with reduced ejection fraction
2016-002280-34Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) and chronic heart failure (CHF) comparing Empagliflozin 10 mg once daily with Placebo once daily (2 arms). Primary endpoint: Time to first event of adjudicated cardiovascular death or adjudicated hospitalization for heart failure. Started Dec 2016; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)chronic heart failure (CHF)
Beyond the preview
Go deeper on 2016-002280-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002280-34.